TY - JOUR
T1 - Breast cancer stage at diagnosis in a New Jersey cancer education and early detection site
AU - Jerome-D'Emilia, Bonnie
AU - Kushary, Debashis
AU - Burrell, Sherry A.
AU - Suplee, Patricia D.
AU - Hansen, Katherine
N1 - Publisher Copyright:
Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.
PY - 2018/11/1
Y1 - 2018/11/1
N2 - Objectives: The National Breast and Cervical Cancer Early Detection Program provides free or low-cost screening to uninsured or underinsured women and has had positive results; however, only a few state programs have been evaluated. This study will provide a first snapshot of the effectiveness of the New Jersey program, by comparing stage at diagnosis for enrollees as compared with nonenrollees who received definitive treatment for breast cancer at the same academic medical center. Materials and Methods: A retrospective analysis of 5 years of breast cancer data abstracted from the Cancer Registry of a large urban hospital in the Northeast United States. Bivariate analysis and logistic regression were utilized. Results: One thousand forty women were screened for and diagnosed with breast cancer at this site; they were more likely to be racially (P<0.001) and ethnically (P<0.002) diverse as compared with nonenrollees. Enrollees were more likely to be symptomatic at diagnosis (P<0.001), and diagnosed at a late stage when compared with nonenrollees (odds ratio, 1.88; 95% confidence interval, 1.07-3.29). Conclusions: This national program was developed to serve low income, under and uninsured women who may otherwise have limited access to cancer screening services. It appears that many women enroll in this program needing diagnostic rather than screening services, after breast symptoms were noted. This finding helps to emphasize the fact that just providing free screening services is not enough to make up for the lack of a usual source of preventive care for low income and uninsured women.
AB - Objectives: The National Breast and Cervical Cancer Early Detection Program provides free or low-cost screening to uninsured or underinsured women and has had positive results; however, only a few state programs have been evaluated. This study will provide a first snapshot of the effectiveness of the New Jersey program, by comparing stage at diagnosis for enrollees as compared with nonenrollees who received definitive treatment for breast cancer at the same academic medical center. Materials and Methods: A retrospective analysis of 5 years of breast cancer data abstracted from the Cancer Registry of a large urban hospital in the Northeast United States. Bivariate analysis and logistic regression were utilized. Results: One thousand forty women were screened for and diagnosed with breast cancer at this site; they were more likely to be racially (P<0.001) and ethnically (P<0.002) diverse as compared with nonenrollees. Enrollees were more likely to be symptomatic at diagnosis (P<0.001), and diagnosed at a late stage when compared with nonenrollees (odds ratio, 1.88; 95% confidence interval, 1.07-3.29). Conclusions: This national program was developed to serve low income, under and uninsured women who may otherwise have limited access to cancer screening services. It appears that many women enroll in this program needing diagnostic rather than screening services, after breast symptoms were noted. This finding helps to emphasize the fact that just providing free screening services is not enough to make up for the lack of a usual source of preventive care for low income and uninsured women.
KW - Breast cancer
KW - Disparities
KW - National Breast and Cervical Cancer Early Detection Program
UR - http://www.scopus.com/inward/record.url?scp=85041559043&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041559043&partnerID=8YFLogxK
U2 - 10.1097/COC.0000000000000425
DO - 10.1097/COC.0000000000000425
M3 - Article
C2 - 29360645
AN - SCOPUS:85041559043
SN - 0277-3732
VL - 41
SP - 1043
EP - 1048
JO - American Journal of Clinical Oncology: Cancer Clinical Trials
JF - American Journal of Clinical Oncology: Cancer Clinical Trials
IS - 11
ER -